Companion Diagnostics Market Growth to a 7.1% CAGR Through 2032
The Companion Diagnostics Market is projected to grow significantly, with its size expected to reach USD 4,786 million by 2032 from USD 2,452 million in 2022, at a CAGR of 7.1% during the forecast period. This growth is driven by several factors including the rising prevalence of chronic diseases, particularly cancer, which necessitates targeted therapies and personalized medicine. Technological advancements, such as the development of next-generation sequencing (NGS) and polymerase chain reaction (PCR) kits, are enhancing the accuracy and effectiveness of companion diagnostics. Recent developments in the market highlight the FDA approvals for various CDx tests, such as Roche's Cobas…
- Date: May 21, 2024
- Author: Robert Shaw
- Category: PharmiWeb